Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

ABN					
95 112 4	125 788				
We (th	We (the entity) give ASX the following information.				
	I - All issues at complete the relevant sections (attack	h sheets if there is not enough space).			
1	*Class of *securities issued or to be issued	Ordinary fully paid shares			
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued				
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)				

Name of entity

Pilbara Minerals Limited

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	\$0.05 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	The issue of shares was pursuant to an exercise of 1,000,000 options with an exercise price of \$0.05 per share, and expiry date of 22 December 2016.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	60,631,474

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	33,649,473 7.1A N/A	
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	14 July 2015	
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	661,578,603	Ordinary fully paid shares

<sup>+</sup> See chapter 19 for defined terms.

9	Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)	27,719,994	Options with an exercise price of \$0.03 and an expiration date of March 25, 2017
		159,950	Convertible Notes with a face value of \$1.00 per note maturing on the earlier of a Conversion Date or 25 September 2015
		815,050	Convertible Notes with a face value of \$1.00 per note maturing on the earlier of a Conversion Date or 30 November 2015
		1,700,000	Convertible Notes with a face value of \$1.00 per note maturing on the earlier of a Conversion Date or 30 November 2015
		4,000,000	Convertible Notes with a face value of \$1.00 per note maturing on the earlier of a Conversion Date or 18 months from date of issue (yet to be issued)
		9,750,000	Options with an exercise price of \$0.05 and an expiration date of December 22, 2016
		50,000,000	Options with an exercise price of \$0.05 and an expiration date of 18

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 4 04/03/2013

			months from date of issue (yet to be issued)
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	
Part 2	- Pro rata issue		
11	Is security holder approval required?	N/A	
		N/A	
12	Is the issue renounceable or non-renounceable?	N/A	
		N/A	
13	Ratio in which the *securities will be offered	N/A	
		N/A	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A	
		N/A	
15	<sup>+</sup> Record date to determine entitlements	N/A	
_		27/4	
16	Will holdings on different registers (or subregisters) be aggregated for calculating	N/A	
	entitlements?		
		N/A	
17	Policy for deciding entitlements in relation to fractions	N/A	
		N/A	
18	Names of countries in which the	N/A	
	entity has security holders who will not be sent new offer documents	14/1	
	Note: Security holders must be told how their entitlements are to be dealt with.		
	Cross reference: rule 7.7.	N.//	
		N/A	
19	Closing date for receipt of acceptances or renunciations	N/A	

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B New issue announcement

20	Names of any underwriters	N/A
		N/A
21	Amount of any underwriting fee	N/A
	or commission	
		N/A
22	Names of any brokers to the issue	N/A
		NT/A
	T 11	N/A
23	Fee or commission payable to the broker to the issue	N/A
	broker to the issue	NI/A
	Amount of any bandling for	N/A
24	Amount of any handling fee payable to brokers who lodge	N/A
	acceptances or renunciations on	
	behalf of security holders	
	bendin of security moracis	N/A
25	If the issue is contingent on	N/A
<del>2</del> )	security holders' approval, the	IN/A
	date of the meeting	
	3	
26	Date entitlement and acceptance	N/A
	form and offer documents will be	,
	sent to persons entitled	
		N/A
27	If the entity has issued options,	N/A
	and the terms entitle option	
	holders to participate on exercise,	
	the date on which notices will be	
	sent to option holders	
		N/A
28	Date rights trading will begin (if	N/A
	applicable)	NT/A
	D	N/A
29	Date rights trading will end (if	N/A
	applicable)	
30	How do security holders sell their	N/A
50	entitlements in full through a	14/71
	broker?	
		N/A
31	How do security holders sell part	N/A
7	of their entitlements through a	<i>'</i>
	broker and accept for the	
	balance?	

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
	,	N/A
33	<sup>+</sup> Issue date	N/A
	3 - Quotation of securities d only complete this section if you are app	
34	Type of *securities (tick one)	
(a)	*Securities described in Part	t 1
(b)	All other *securities	
	*	end of the escrowed period, partly paid securities that become fully paid een restriction ends, securities issued on expiry or conversion of convertible
Entitie	es that have ticked box 34(a)	
Additi	ional securities forming a new	class of securities
Tick to docum	o indicate you are providing the informatents	tion or
35	1 1	v securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36	1 1	y securities, a distribution schedule of the additiona umber of holders in the categories
	1 - 1,000	
	1,001 - 5,000 5,001 - 10,000	
	10,001 - 100,000	
	100,001 and over	
37	A copy of any trust deed for	the additional *securities
	_	

<sup>+</sup> See chapter 19 for defined terms.

Entities that have ticked box 34(b)			
38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another *security clearly identify		
	another *security, clearly identify that other *security)	Number	+Class
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	+Class

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the †securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>†</sup>quotation of the <sup>†</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

<sup>+</sup> See chapter 19 for defined terms.

Sign here:

Date: 14 July 2015

(Company secretary)

Print name: Alan Boys

== == == ==

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base fig capacity is calculated	ure from which the placement	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	330,297,262	
Add the following:		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2	120,889,064	
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul>	177,353,326	
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
Subtract the number of fully paid  †ordinary securities cancelled during that  12 month period	Nil	
"A"	628,539,652	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"			
"B"	94,280,947		
Multiply "A" by 0.15			
Step 3: Calculate "C", the amount 7.1 that has already been used	of placeme	ent capacity under rule	
<ul> <li>Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:</li> <li>Under an exception in rule 7.2</li> </ul>	18,848,868 17,842,523	Previous Issues  Being Shares at a  Conversion Price of  \$0.095278 being 80% of the	
<ul> <li>Under rule 7.1A</li> <li>With security holder approval under rule 7.1 or rule 7.4</li> <li>Note:</li> <li>This applies to equity securities, unless</li> </ul>		prior 5 day VWAP on 22 June 2015 in respect of Convertible Notes with a face value of \$1,700,000 which mature on 22 December 2016	
<ul> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	23,150,000	Options exercisable at \$0.05 and expiring on 22 December 2016  Ordinary shares issued in respect of interest on convertible notes	
	679,686	Issued in satisfaction of supplier invoice	
"C"	60,631,474		
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1			
"A" x 0.15	94,280,947		
Note: number must be same as shown in Step 2			
Subtract "C"	60,631,474		
Note: number must be same as shown in Step 3			
<i>Total</i> ["A" x 0.15] – "C"	33,649,473 [Note: this is the remaining placement capacity under rule 7.1]		

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"D"	0.10  Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	N/A	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<ul> <li>Insert number of †equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	N/A	
"E"	N/A	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10  Note: number must be same as shown in Step 2		
Subtract "E"  Note: number must be same as shown in Step 3	N/A	
<i>Total</i> ["A" x 0.10] – "E"	N/A Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 14 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.